16 September 2026 note archive · Trial
SURPASS-T1D-2: tirzepatide longer-term study in adults with T1D and overweight or obesity: review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT06962280; ACTIVE_NOT_RECRUITING; updated 2026-02-17; enrollment 465 (ESTIMATED); results not posted.
Endpoint comparison: Change from Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 40).
Sources for this record: NCT06962280: Long-term tirzepatide safety in T1D with overweight or obesity (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.